Trigemina expands Phase II trial of TI-001 for chronic migraine
The Phase II TRIG-05 trial is assessing TI-001, an investigational, nasally-delivered oxytocin therapeutic currently being examined to determine its efficacy, tolerability, and safety in chronic migraine patients. Secondary